Airway IL-1β and systemic inflammation as predictors of future exacerbation risk in asthma and COPD

Chest

Volumn 148, Issue 3, 2015, Pages 618-629

  Fu, Juan Juan ^a,b   McDonald, Vanessa M ^b,c   Baines, Katherine J ^b,d   Gibson, Peter G ^b,d  

^a SICHUAN UNIVERSITY   (China)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c UNIVERSITY OF NEWCASTLE   (Australia)

^d HUNTER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6;

ADULT; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE EXACERBATION; FEMALE; FOLLOW UP; GENE EXPRESSION; HUMAN; IL 1BETA GENE; IMMUNOREACTIVITY; INFLAMMATION; INNATE IMMUNITY; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR; AGED; CHEMISTRY; COMORBIDITY; GENETICS; IMMUNOLOGY; MIDDLE AGED; QUESTIONNAIRE; SPIROMETRY; SPUTUM;

AGED; ASTHMA; BIOMARKERS; C-REACTIVE PROTEIN; COMORBIDITY; FEMALE; GENE EXPRESSION; HUMANS; INFLAMMATION; INTERLEUKIN-1BETA; INTERLEUKIN-6; MALE; MIDDLE AGED; PHENOTYPE; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SPIROMETRY; SPUTUM; SURVEYS AND QUESTIONNAIRES;

EID: 84941618361     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.14-2337     Document Type: Conference Paper

References (33)

1. Connors AF Jr, Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med. 1996; 154 ( 4 pt 1): 959-967.
2. McDonald VM, Gibson PG. Exacerbations of severe asthma. Clin Exp Allergy. 2012; 42 ( 5): 670-677.
3. Bai TR, Vonk JM, Postma DS, Boezen HM. Severe exacerbations predict excess lung function decline in asthma. Eur Respir J. 2007; 30 ( 3): 452-456.
4. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002; 57 ( 10): 847-852.
5. Kupczyk M, ten Brinke A, Sterk PJ, et al; BIOAIR investigators. Frequent exacerbators-A distinct phenotype of severe asthma. Clin Exp Allergy. 2014; 44 ( 2): 212-221.
6. Spencer S, Calverley PM, Burge PS, Jones PW. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J. 2004; 23 ( 5): 698-702.
7. Dougherty RH, Fahy JV. Acute exacerbations of asthma: epidemiology, biology and the exacerbation-prone phenotype. Clin Exp Allergy. 2009; 39 ( 2): 193-202.
8. Hurst JR, Vestbo J, Anzueto A, et al; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010; 363 ( 12): 1128-1138.
9. ten Brinke A, Sterk PJ, Masclee AA, et al. Risk factors of frequent exacerbations in diffi cult-to-treat asthma. Eur Respir J. 2005; 26 ( 5): 812-818.
10. Miravitlles M, Calle M, Soler-Cataluña JJ. Clinical phenotypes of COPD: identifi cation, defi nition and implications for guidelines. Arch Bronconeumol. 2012; 48 ( 3): 86-98.
11. Simpson JL, Grissell TV, Douwes J, Scott RJ, Boyle MJ, Gibson PG. Innate immune activation in neutrophilic asthma and bronchiectasis. Thorax. 2007; 62 ( 3): 211-218.
12. Wood LG, Baines KJ, Fu J, Scott HA, Gibson PG. The neutrophilic infl ammatory phenotype is associated with systemic infl ammation in asthma. Chest. 2012; 142 ( 1): 86-93.
13. Donaldson GC, Seemungal TA, Patel IS, et al. Airway and systemic infl ammation and decline in lung function in patients with COPD. Chest. 2005; 128( 4): 1995-2004.
14. Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007; 175 ( 3): 250-255.
15. Agustí A, Edwards LD, Rennard SI, et al; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Persistent systemic infl ammation is associated with poor clinical outcomes in COPD: A novel phenotype. PLoS ONE. 2012; 7 ( 5): e37483.
16. Thomsen M, Ingebrigtsen TS, Marott JL, et al. Infl ammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. J AMA. 2013; 309 ( 22): 2353-2361.
17. Slack J, McMahan CJ, Waugh S, et al. Independent binding of interleukin-1 alpha and interleukin-1 beta to type I and type II interleukin-1 receptors. J Biol Chem. 1993; 268 ( 4): 2513-2524.
18. Baines KJ, Simpson JL, Wood LG, Scott RJ, Gibson PG. Transcriptional phenotypes of asthma defi ned by gene expression profi ling of induced sputum samples. J Allergy Clin Immunol. 2011;127(1):153-160.
19. Pauwels NS, Bracke KR, Dupont LL, et al. Role of IL-1 a and the Nlrp3/caspase-1/ IL-1 b axis in cigarette smoke-induced pulmonary infl ammation and COPD. Eur Respir J. 2011; 38 ( 5): 1019-1028.
20. Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructivepulmonary disease: identifi cation of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011; 184( 6): 662-671.
21. Fu JJ, Baines KJ, Wood LG, Gibson PG. Systemic infl ammation is associated with diff erential gene expression and airway neutrophilia in asthma. OMICS. 2013; 17 ( 4): 187-199.
22. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40 ( 5): 373-383.
23. Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999; 14 ( 4): 902-907.
24. Gibson PG, Wlodarczyk JW, Hensley MJ, et al. Epidemiological association of airway infl ammation with asthma symptoms and airway hyperresponsiveness in childhood. Am J Respir Crit Care Med. 1998; 158 ( 1): 36-41.
25. Reddel HK, Taylor DR, Bateman ED, et al; American Thoracic Society/European Respiratory Society Task Force on Asthma Control and Exacerbations. An offi cial American Thoracic Society/European Respiratory Society statement: Asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009; 180 ( 1): 59-99.
26. Brusselle GG, Vanderstichele C, Jordens P, et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): A multicentre randomised double-blind placebo-controlled trial. Thorax. 2013; 68 ( 4): 322-329.
27. Agustí A. Systemic effects of chronic obstructive pulmonary disease: what we know and what we don't know (but should). Proc Am Thorac Soc. 2007; 4 ( 7): 522-525.
28. Lei PW, Wu Q. Introduction to structural equation modeling: issues and practical considerations. Educ Meas Issues Pract. 2007; 26 ( 3): 33-43.
29. Dolinay T, Kim YS, Howrylak J, et al. Infl ammasome-regulated cytokines are critical mediators of acute lung injury. Am J Respir Crit Care Med. 2012; 185 ( 11): 1225-1234.
30. Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: A randomised controlled trial. Lancet. 2002; 360 ( 9347): 1715-1721.
31. Jayaram L, Pizzichini MM, Cook RJ, et al. Determining asthma treatment by monitoring sputum cell counts: eff ect on exacerbations. Eur Respir J. 2006; 27 ( 3): 483-494.
32. Gibson PG, Fujimura M, Niimi A. Eosinophilic bronchitis: clinical manifestations and implications for treatment. Thorax. 2002; 57 ( 2): 178-182.
33. Global strategy for the diagnosis, management and prevention of COPD. GOLD website. http://www. goldcopd. com. Updated 2014. Accessed August 30, 2015.